On Tuesday, The Food and Drug Administration (FDA) issued draft guidance that would create a set of rules for researching cannabis. While forming the guidance the FDA drew on a 2019 public hearing during which industry representatives expressed concern about inaccurate or misleading marketing for products with CBD that are not regulated by the FDA. The guidance will inform researchers how to lawfully conduct cannabis research and is “limited to the development of human drugs and does not cover other FDA-regulated products”. Recent legislative changes have also opened new opportunities for cannabis clinical research but, many Marijuana advocates believe the new guidance falls short of substantive policy change.
– The Hill, July 21, 2020